MV Capital Management Inc. Sells 770 Shares of Johnson & Johnson $JNJ

MV Capital Management Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 4.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,433 shares of the company’s stock after selling 770 shares during the period. MV Capital Management Inc.’s holdings in Johnson & Johnson were worth $2,816,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $35,000. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. Finally, Pandora Wealth Inc. purchased a new stake in Johnson & Johnson in the 1st quarter worth approximately $65,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.4%

Shares of Johnson & Johnson stock opened at $194.52 on Thursday. The firm has a market cap of $468.65 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $195.55. The company has a 50-day moving average of $185.13 and a 200 day moving average of $169.48.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion during the quarter. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JNJ. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. UBS Group upped their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Citigroup upped their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Finally, Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.